Next Article in Journal
NoxO1 Knockout Promotes Longevity in Mice
Previous Article in Journal
Gelidium amansii Attenuates Hypoxia/Reoxygenation-Induced Oxidative Injury in Primary Hippocampal Neurons through Suppressing GluN2B Expression
Previous Article in Special Issue
Design of Light-Sensitive Triggers for Endothelial NO-Synthase Activation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 9
Issue 3
10.3390/antiox9030225
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

An Update on Thiol Signaling: S-Nitrosothiols, Hydrogen Sulfide and a Putative Role for Thionitrous Acid

by
Nadzeya Marozkina
1,2,* and
Benjamin Gaston
1
1
Herman Wells Center for Pediatric Research, Riley Hospital for Children, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
2
Indiana University, School of Medicine, 1044 W. Walnut Street, R4-474 Indianapolis, IN 46202, USA
*
Author to whom correspondence should be addressed.
Antioxidants 2020, 9(3), 225; https://doi.org/10.3390/antiox9030225
Submission received: 27 January 2020 / Revised: 25 February 2020 / Accepted: 3 March 2020 / Published: 10 March 2020
(This article belongs to the Special Issue NO(NOx) and H2S)
Browse Figure
Review Reports Versions Notes

Abstract

:
Long considered vital to antioxidant defenses, thiol chemistry has more recently been recognized to be of fundamental importance to cell signaling. S-nitrosothiols—such as S-nitrosoglutathione (GSNO)—and hydrogen sulfide (H2S) are physiologic signaling thiols that are regulated enzymatically. Current evidence suggests that they modify target protein function primarily through post-translational modifications. GSNO is made by NOS and other metalloproteins; H2S by metabolism of cysteine, homocysteine and cystathionine precursors. GSNO generally acts independently of NO generation and has a variety of gene regulatory, immune modulator, vascular, respiratory and neuronal effects. Some of this physiology is shared with H2S, though the mechanisms differ. Recent evidence also suggests that molecules resulting from reactions between GSNO and H2S, such as thionitrous acid (HSNO), could also have a role in physiology. Taken together, these data suggest important new potential targets for thiol-based drug development.

1. Introduction

Thiol chemistry has recently been recognized to be important for the regulation of cell signaling processes. S-nitrosoglutathione (GSNO) and other S-nitrosothiols, as well as hydrogen sulfide (H2S), are enzymatically-regulated cell signaling thiols, affecting target protein function through post-translational modifications. Regulation of the metabolism of GSNO, of other S-nitrosothiols and of H2S (Figure 1) are vital to immune, vascular, respiratory and neuronal signaling. Here, we will review data regarding the role and regulation of these molecules in physiology.

2. Overview of S-Nitrosothiol Metabolism

2.1. Production of S-Nitrosothiols and Other Nitrogen Oxides In Vivo

Nitric oxide synthases (NOS) use the guanidino nitrogen of l-arginine [1,2,3,4] to form NO, and GSNO is also often formed when NOS is activated [5,6,7,8]. Three principal isoforms of NOS exist [9,10,11]. These are neuronal (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). Activation of all three can result in downstream S-nitrosothiol formation [6,9,10,12] (Figure 1). Reactions of NO with thiols are typically kinetically favored to occur through interactions with metalloproteins rather than through inorganic NO oxidation. Typically, they involve NO oxidation to NO+. NO is oxidized by reactions with superoxide and with certain metal ions. NO also reacts with oxygen, but this reaction is third order (third order rate constant ~7 × 103 L2 mol−2 sec−1) [13]: The reaction is normally quite slow in physiology because the concentrations of NO in the body gas phase are ~nM. The reaction rate is favored in membranes [14] because the reactants are more soluble in lipid than water. As discussed more below, GSNO and other S-nitrosothiols are typically formed through reactions of NO with iron and copper groups in these metalloproteins (including NOSs), though there is evidence also for formation of a complex with an amine of NOS-bound tetrahydrobiopterin (BH4) [15] and other reactions [16]. Other metalloproteins involved in S-nitrosothiol formation include Hb, where S-nitrosylation occurs at the b-93 cysteine [17], and ceruloplasmin [18].
Endothelial NOS provides an example of the role of S-nitrosothiol formation and NO in biology [19,20,21]. We and others have shown that eNOS activation can result in S-nitrosothiol formation [12,22]. Moreover, GSNO catabolism by GSNO reductase is required to reverse and or modulate the effects of eNOS, suggesting that, in physiology, GSNO is a regulated eNOS product [19,23]. At the myoendothelial junction, eNOS is colocalized with somatic cell hemoglobin alpha [20]. When the iron of the hemoglobin is oxidized, eNOS activation produces NO and S-nitrosothiols; when it is reduced, inert nitrate is formed [22]. Note that impaired activity of eNOS resulting from oxidative stress in the endothelium involves BH4 oxidation [24,25]. This induces the uncoupling of eNOS, with consequent generation of O2− instead of NO [24,26] or GSNO [12]. Endothelial NOS redox chemistry, with products including thiol-stabilized S-nitrosothiols, inert nitrite and nitrate and highly ONOOH, are relevant to a range of vascular diseases [25,26,27,28,29,30,31,32,33,34,35,36]

2.2. S-Nitrosylation Signaling and S-Nitrosothiols

Broadly, thiols modified by a NO+ (RS− - NO+), NO− (R-S+-NO−) or NO (RS-NO) are referred to as S-nitrosothiols [27]. The thiol R group can be a simple proton (thionitrous acid, see below), or can be an amino acid, peptide or protein. S-Nitrosylation is a normally a targeted, post-translational protein cysteine modification with a specific biological purpose. Note that S-nitrosylated proteins may transfer NO to other proteins [28,29,30]. S-nitrosylation is regulated as a signaling reaction. [5,12,31,32]. Regulation of human airway tone provides an example. GSNO is normally present in the human airway at ~500 nM (30), the IC50 for soluble guanylate cyclase (sGC)-independent human airway dilatation [33]. GSNO prevents β2 agonist tachyphylaxis by S-nitrosylating GRK2 downstream of eNOS activation through its effect on β arrestin to [19]. Indeed, tachyphylaxis to β2-AR agonists is ablated in [19,34] mice lacking the ability to reduce GSNO because of deletion of the enzyme, GSNO reductase (GSNOR). These mice are protected from β-AR [34], and humans with gain-of-function in this enzyme are at increased asthma risk [35].
There are many additional examples of signaling caused by GSNO and other S-nitrosothiols [5,6,12,31,32,36]. These molecules regulate a broad range of bioactivities, ranging from coagulation and N-methyl-d-aspartate (NMDA) dependent neuronal signaling [37,38]. In many cases, NO+ is transferred from a low-mass S-nitrosothiol to a protein thiol. A recent example involves S-nitrosylation of connexin 43 (Cx43) hemichannels in the Duchenne Muscular Dystrophy (Dmd) heart that has been driven by β2 agonists to develop stress-induced arrhythmias: inhibition of NOS prevents arrhythmias evoked by isoproterenol [39]. NOS activation results in S-nitrosylation of Cx43 at cysteine 271, regulating arrhythmia risk. [39].
Other mechanisms of thiol modification are relevant as well. Myeloperoxidase causes protein thiol S-nitrosylation at tyrosine-Xn-cysteine (YXnC) motifs in the presence of hydrogen peroxide and nitrite [16]. Inorganic S-nitrosylation can occur at low pH, particularly in the mitochondrial intermembrane space [40], in the lung and gut, and in the blood vessels in ischemic tissues [41,42]. In the case of hemoglobin- and ceruloplasmin-mediated S-nitrosylation, NO radical normally first reduces the metal: Fe3+-NO transitions to Fe2+-NO+; Cu2+- NO transitions to Cu+-NO+. Of note, GSNO can serve as an intermediate to transfer the NO+ equivalent from a metalloprotein to a target thiolate.
Note that the GSNO breakdown product, S-nitroso-L-cysteine (L-CSNO), is increasingly appreciated as a stereoselective signaling molecule. L-CSNO was originally considered an endothelium derived relaxing factor (EDRF) [43,44,45,46]. Lewis, Bates and others observed that the L-isomers of CSNO and related S-nitrosothiols were substantially more active than the D-isomers, though they evolve NO equally [47,48,49]. Their findings suggest that L-CSNO activates stereoselective recognition sites [50]. In guinea-pig myocytes, L-CSNO activates large conductance Ca2+ activated K+-channels by S-nitrosylation of the alpha subunit [51]. In porcine coronary arteries, L-CSNO activates intermediate and small conductance Ca2+-activated K+-channels. S-nitroso-D-cysteine (D-CSNO) does not have these effects [45,46]. Ca2+-activated K+-channels activation causes vasorelaxation exclusively from voltage-gated Ca2+ channel closures induced by hyperpolarization [52]. Though nifedipine, a voltage-gated Ca2+ +channel blocker, reduces vasodilator responses from donors of NO, it does not reduce the responses of L-CSNO or the release of EDRF by acetylcholine [52].
Signaling mediated by S-nitrosothiols is not unique to mammalian physiology: it is vital in plant biology and in microbiology. Interaction between eukaryotic host and its microbiome has been shown to be affected by inter-species S-nitrosothiol signaling [53]. For example, prokaryotic S-nitrosothiol signaling uses the hybrid-cluster protein Hcp downstream of nitrate reductase. Here, the complex interactions of S-nitrosothiol synthases and transnitrosylases signal E. Coli mobility and metabolism [36].

2.3. Denitrosylation

Like other post-translational modifications, S-nitrosylation signaling is balanced by the reverse effect, denitrosylation. Many enzymes function as denitrosylases. Commonly, these use NAD(P)H oxidation to reduce S-nitrosothiols. Examples include NADH-dependent GSNO reductase (see below) and NADPH-dependent SNO-Coenzyme A reductase (Figure 1). Many additional enzyme systems catabolize GSNO, the details of which are beyond the scope of this review [54,55,56,57,58,59,60] Products can include another S-nitrosothiols, NO, ONOOH, NH2OH and NH3. SNO-CoA reductase is also known as aldo-keto reductase family 1 member A1 (AKR1A1) (Figure 1). AKR1A1 can catabolize both SNO-CoA and GSNO [61].
These S-nitrosothiol catabolic enzymes play critical roles in human physiology. For example, GSNOR gene variants affect asthma prevalence and β2 agonist responsiveness in specific human asthma subpopulations [35,62,63]; we have identified a specific severe asthmatic population phenotype associated with high GSNOR activity [64]. Denitrosylation functions are vital, as evidenced by functional redundancy. For example, GSNOR -/- mice have more AKR1A1 GSNO catabolic activity than do wild type mice [61].

3. Hydrogen Sulfide Production and Metabolism In Vivo. Similarities and Differences of NO and H2S Metabolism

Like GSNO, H2S is a thiol-based mediator that is produced enzymatically and is active in physiology at low, endogenous concentrations [65,66,67]. Hydrogen sulfide is produced by mammalian enzymes cystathione-lyase(CSE), cystathione-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (3-MST) [68]. Additionally, cysteine aminotransferase (CAT) produces 3-mercaptopyruvate substrate for 3MST to produce a protein-bound persulfide, that in turn can be reduced to form H2S [69,70] (Figure 1), and, in plants, by desulfhydrases [71]. Note that CBS and CSE are multifunctional enzymes catalyzing a range of β replacement and α, β and γ elimination reactions: Their roles in thiol chemistry can often be redundant (Figure 1). The substrate for 3MST is 3-mercaptopyruvate; others can use L-cysteine, cystathione and other substrates (Figure 1).
As with S-nitrosothiol-based signaling, H2S can affect physiology by causing post-translational modifications of protein thiols. Also as with S-nitrosothiols, specific enzymes also break down H2S [72]. For example, mitochondrial rhodanese, a sulfur transferase, catalyzes H2S oxidation [73], as a component of a major H2S catabolic pathway that also involves a sulfide quinone oxido-reductase (SQR) and a sulfur dioxygenase. H2S catabolic enzymes are extensively reviewed in ref [74]. Additionally, iron-containing proteins, such as hemoglobin and cytochrome C oxidase, also can serve as sinks for H2S (71,77).
The first physiological protein target identified for H2S involved vasodilatation mediated by H2S modification of the K ATP (Kir6.x) channel [75]. Like S-nitrosothiols, H2S also acts through post-translational modifications of protein. The key reaction is defined as S-sulfhydration [76,77], the forming protein –SSH moieties. This S-sulfhydration reactions can modify a large number of proteins, including GAPDH (at Cys150), albumin, actin, ADH1, AST, catalase and thioredoxin-reductase [76]. Indeed, there could well be cross-talk between S-nitrosylation and S-sulfhydration signaling [78].
Inhibition of NOS by the nonspecific inhibitor L-NAME leads to inhibition of H2S-induced vasodilation [79,80,81], while the deletion of CSE (cystathionine γ-lyase) enhances the vasodilatory effects of acetylcholine [82].
Like S-nitrosothiols, H2S signaling has a role in regulating vascular tone. CSE−/− mice have increased blood pressure as they age [83]. Isolated vessels from CSE−/− mice have significantly impaired methacholine-induced vasodilatation. Of note, activation of endothelial CSE and eNOS are both Ca2+-calmodulin dependent [83,84]; and both can involve cGMP and phosphodiesterases, with competing effects. [85,86].
In contrast to some of the more labile S-nitrosothiols; however, H2S is relatively stable in certain body compartments. However, it can be metabolized by methylation or oxidation, and its products excreted in urine [87,88]. It is also is scavenged by its reactions with heme. H2S for example, because of its interaction with mitochondrial cytochrome c oxidase [67,89], can be toxic at higher concentrations [90,91]. Two H2S oxidative pathways have been identified recently and involve cytosolic ferric (met) hemoglobin (Hb) in red blood cells [92] and myoglobin (Mb) in the heart [93]. Both of these proteins have the capability to generate heme-bound polysulfides and free thiosulfates as end-products. Decreasing pH (across the range 8–6.8) decreases heme H2S-affinity by causing a right-shift in the binding of H2S to metHb. Equilibrium dissociation constants of metHb and H2S are in the range of 0.26–1.08 μM, which is well below that for NO it (~100 μM) [94] and CN−(~10 μM) [95], among other metHb ligands. This indicated that H2S is a high-affinity metHb ligand. Rate constants for metHb (3.2 × 103M−1s−1) [37] and metMb (1.6 × 104M−1s−1) [96] suggest that metHb is a reversible H2S carrier, affecting H2S bioactivities [95].

Thionitrous Acid and Related Compounds

Thionitrous acid (HSNO) is another low molecular weight thiol that may be relevant to signaling. HSNO can be formed by reactions between hydrogen sulfide (H2S) and S-nitrosothiols [97,98,99]. For example, HSNO is produced rapidly according to, H2S + GSNO → HSNO + GSH. Theoretically, HSNO can also be formed by the reaction N2O3 → HSNO + HNO2. However, as noted above, N2O3 is not formed abundantly in most physiological systems.
It has been shown that the NaHS/GSNO reaction products relax precontracted rat aortic rings with pharmacology consistent with the relevance of HSNO or SNO-intermediates. These are dependent on heme concentrations, as well as pH [100]. Of note, there is evidence that HSNO can diffuse through membranes to signal in physiology [98], supporting a possible role as a signaling molecule. Note, however, that the pKa of HSNO is low, and HSNO in physiology may exist as the SNO− anion. A molecule, QT490, has been developed that forms HSNO and provides insight into formation of HSNO/RSNO from the reaction between H2S/RSH and NO in the biological system [101].
It is also possible that HNO and HSSH could be formed from HSNO with H2S. The resulting S–N bond is the longest reported S–N bond for an R-SNO compound, 1.84 Å [102]. The tautomeric form of HSNO is more thermodynamically feasible and kinetically accessible [103]. These reactions could also form bioactive nitroxyl HNO [103]. HNO is a powerful vasodilator. While NO reacts slowly with thiols, the reaction of HNO with thiols is very fast and it depends on the pKa of the reacting thiolate [104]. Rapid HNO production can also occur in small-to-medium-sized sensory neurons and axons, where it was observed to be co-expression of CBS (cystathionine beta synthase) with TRPA1 (transient receptor potential channel A1) [79]. TRPA1 is the Ca2+ ion channel responsible for CGRP release induced by HNO), [79] which is known to be co-expressed with nNOS. Reactive cysteine residues on TRPA1 become oxidized by HNO, resulting in long-lasting channel opening, Ca2+ influx, and subsequent release of CGRP [105]. These three proteins, CBS, nNOS, and TRPA1, represent a functional unit that is involved in the regulation of peripheral blood flow [106] and even the regulation of systemic blood pressure [79] It has been hypothesized that the disturbances in the regulation of this pathway might be responsible for the migraine attacks [106].
Taken together, these data suggest the possible relevance of HSNO at the interface of S-nitrosothiol and H2S signaling.

4. Conclusions

Small thiol molecules have cell signaling effects in physiological concentrations. Both S-nitrosothiols and H2S can be formed and broken down by specific regulatory proteins. Both have physiological effects involving post-translational modifications, primarily at cysteine residues, but the mechanisms are different. Once considered primarily valuable for breaking disulfide bods to reduce viscosity and/or to augment antioxidant defenses, thiol chemistry is beginning to be recognized as relevant to cell signaling reactions. These recent observations suggest that thiol chemistry may be more useful than previously thought for new drug development.
However, more work needs to be done to understand in greater details the roles of S-nitrosothiols and of H2S in physiology, and to determine the degree to which HSNO chemistry is relevant to biology.

Author Contributions

N.M.: Writing—review and editing, conceptualization, resources. B.G.: Project administration, funding acquisition, supervision. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by: NIIH/NHLBI P01 HL128192, Riley Children’s Foundation, Eli Lilly Foundation INCITE program.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AKR1A1—aldoketoreductase family 1 member 1A, CAT—cysteine aspartate aminotransferase, CBS—cystathione b—synthase, CSE—cystathione gamma lyase, CDO—cysteine deoxygenase, CoA—Coenzyme A, C-SNO—S-nitrosocysteine, GSNO—S-nitrosoglutathione, GSNOR—S-nitrosoglutathione reductase, GS—glutathione synthase, GCS—glutamylcysteine synthase, MAT—methionine adenosyltransferase; SAM—S-adenosyl methionine; 3MST—3 mercaptopuruvate sulfur transferase, PTA—pantetheinase, SNO-CoA—S-nitroso-Coenzyme A, γGT—γglutamyl transpeptidase.

References

  1. Hibbs, J.B., Jr.; Vavrin, Z.; Taintor, R.R. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J. Immunol. 1987, 138, 550–565. [Google Scholar] [PubMed]
  2. Babu, B.R.; Frey, C.; Griffith, O.W. L-arginine binding to nitric-oxide synthase. The role of H-bonds to the nonreactive guanidinium nitrogens. J. Biol. Chem. 1999, 274, 25218–25226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Southan, G.J.; Srinivasan, A. Nitrogen oxides and hydroxyguanidines: Formation of donors of nitric and nitrous oxides and possible relevance to nitrous oxide formation by nitric oxide synthase. Nitric Oxide 1998, 2, 270–286. [Google Scholar] [CrossRef] [PubMed]
  4. Vicente, F.B.; Vespa, G.; Miller, A.; Haymond, S. Quantification of Arginine and Its Methylated Derivatives in Plasma by High-Performance Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Methods Mol. Biol. 2016, 1378, 21–30. [Google Scholar] [CrossRef] [PubMed]
  5. Marozkina, N.V.; Gaston, B. S-Nitrosylation signaling regulates cellular protein interactions. Biochim. Biophys. Acta 2012, 1820, 722–729. [Google Scholar] [PubMed] [Green Version]
  6. Marozkina, N.V.; Gaston, B. Nitrogen chemistry and lung physiology. Annu. Rev. Physiol. 2015, 77, 431–452. [Google Scholar] [CrossRef]
  7. Smith, B.C.; Marletta, M.A. Mechanisms of S-nitrosothiol formation and selectivity in nitric oxide signaling. Curr. Opin. Chem. Biol. 2012, 16, 498–506. [Google Scholar] [CrossRef] [Green Version]
  8. Blonder, J.P.; Mutka, S.C.; Sun, X.; Qiu, J.; Green, L.H.; Mehra, N.K.; Boyanapalli, R.; Suniga, M.; Look, K.; Delany, C.; et al. Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation. BMC Pulm. Med. 2014, 14, 3. [Google Scholar] [CrossRef] [Green Version]
  9. Kobzik, L.; Bredt, D.S.; Lowenstein, C.J.; Drazen, J.; Gaston, B.; Sugarbaker, D.; Stamler, J.S. Nitric oxide synthase in human and rat lung: Immunocytochemical and histochemical localization. Am. J. Respir. Cell Mol. Biol. 1993, 9, 371–377. [Google Scholar] [CrossRef]
  10. Asano, K.; Chee, C.B.; Gaston, B.; Lilly, C.M.; Gerard, C.; Drazen, J.M.; Stamler, J.S. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc. Natl. Acad. Sci. USA 1994, 91, 10089–10093. [Google Scholar]
  11. Guo, F.H.; De Raeve, H.R.; Rice, T.W.; Stuehr, D.J.; Thunnissen, F.B.; Erzurum, S.C. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. USA 1995, 92, 7809–7813. [Google Scholar] [PubMed] [Green Version]
  12. Gow, A.J.; Chen, Q.; Hess, D.T.; Day, B.J.; Ischiropoulos, H.; Stamler, J.S. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J. Biol. Chem. 2002, 277, 9637–9640. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Tsukahara, H.; Ishida, T.; Mayumi, M. Gas-phase oxidation of nitric oxide: Chemical kinetics and rate constant. Nitric Oxide 1999, 3, 191–198. [Google Scholar] [CrossRef] [PubMed]
  14. Liu, X.; Miller, M.J.; Joshi, M.S.; Thomas, D.D.; Lancaster, J.R., Jr. Accelerated reaction of nitric oxide with O2 within the hydrophobic interior of biological membranes. Proc. Natl. Acad. Sci. USA 1998, 95, 2175–2179. [Google Scholar]
  15. Rosenfeld, R.J.; Bonaventura, J.; Szymczyna, B.R.; MacCoss, M.J.; Arvai, A.S.; Yates, J.R., III; Tainer, J.A.; Getzoff, E.D. Nitric-oxide synthase forms N-NO-pterin and S-NO-cys: Implications for activity, allostery, and regulation. J. Biol. Chem. 2010, 285, 31581–31589. [Google Scholar] [CrossRef] [Green Version]
  16. Zhang, H.; Xu, Y.; Joseph, J.; Kalyanaraman, B. Intramolecular electron transfer between tyrosyl radical and cysteine residue inhibits tyrosine nitration and induces thiyl radical formation in model peptides treated with myeloperoxidase, H2O2, and NO2-: EPR SPIN trapping studies. J. Biol. Chem. 2005, 280, 40684–40698. [Google Scholar] [CrossRef] [Green Version]
  17. Stamler, J.S.; Jia, L.; Eu, J.P.; McMahon, T.J.; Demchenko, I.T.; Bonaventura, J.; Gernert, K.; Piantadosi, C.A. Blood Flow Regulation by S-Nitrosohemoglobin in the Physiological Oxygen Gradient. Science 1997, 276, 2034–2037. [Google Scholar] [CrossRef] [Green Version]
  18. Inoue, K.; Akaike, T.; Miyamoto, Y.; Okamoto, T.; Sawa, T.; Otagiri, M.; Suzuki, S.; Yoshimura, T.; Maeda, H. Nitrosothiol formation catalyzed by ceruloplasmin. Implication for cytoprotective mechanism in vivo. J. Biol. Chem. 1999, 274, 27069–27075. [Google Scholar]
  19. Francis, S.H.; Busch, J.L.; Corbin, J.D.; Sibley, D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62, 525–563. [Google Scholar] [CrossRef]
  20. Mason, M.G.; Nicholls, P.; Wilson, M.T.; Cooper, C.E. Nitric oxide inhibition of respiration involves both competitive (heme) and noncompetitive (copper) binding to cytochrome c oxidase. Proc. Natl. Acad. Sci. USA 2006, 103, 708–713. [Google Scholar] [CrossRef] [Green Version]
  21. Whalen, E.J.; Foster, M.W.; Matsumoto, A.; Ozawa, K.; Violin, J.D.; Que, L.G.; Nelson, C.D.; Benhar, M.; Keys, J.R.; Rockman, H.A.; et al. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell 2007, 129, 511–522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Gaston, B.; Drazen, J.M.; Jansen, A.; Sugarbaker, D.A.; Loscalzo, J.; Richards, W.; Stamler, J.S. Relaxation of human bronchial smooth muscle by S-nitrosothiols in vitro. J. Pharmacol. Exp. Ther. 1994, 268, 978–984. [Google Scholar] [PubMed]
  23. Carver, D.J.; Gaston, B.; Deronde, K.; Palmer, L.A. Akt-mediated activation of HIF-1 in pulmonary vascular endothelial cells by S-nitrosoglutathione. Am. J. Respir. Cell Mol. Biol. 2007, 37, 255–263. [Google Scholar] [CrossRef] [PubMed]
  24. Straub, A.C.; Lohman, A.W.; Billaud, M.; Johnstone, S.R.; Dwyer, S.T.; Lee, M.Y.; Bortz, P.S.; Best, A.K.; Columbus, L.; Gaston, B.; et al. Endothelial cell expression of haemoglobin alpha regulates nitric oxide signalling. Nature 2012, 491, 473–477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Palmer, L.A.; Doctor, A.; Chhabra, P.; Sheram, M.L.; Laubach, V.E.; Karlinsey, M.Z.; Forbes, M.S.; Macdonald, T.; Gaston, B. S-nitrosothiols signal hypoxia-mimetic vascular pathology. J. Clin. Investig. 2007, 117, 2592–2601. [Google Scholar] [CrossRef]
  26. Antoniades, C.; Shirodaria, C.; Crabtree, M.; Rinze, R.; Alp, N.; Cunnington, C.; Diesch, J.; Tousoulis, D.; Stefanadis, C.; Leeson, P.; et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007, 116, 2851–2859. [Google Scholar] [CrossRef] [Green Version]
  27. Antoniades, C.; Tousoulis, D.; Stefanadis, C. Effects of endothelial nitric oxide synthase gene polymorphisms on oxidative stress, inflammatory status, and coronary atherosclerosis: An example of a transient phenotype. J. Am. Coll. Cardiol. 2007, 49, 1226–1227. [Google Scholar] [CrossRef] [Green Version]
  28. Dikalova, A.; Aschner, J.L.; Kaplowitz, M.R.; Summar, M.; Fike, C.D. Tetrahydrobiopterin oral therapy recouples eNOS and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs. Am. J. Physiol. Lung Cell. Mol. Physiol. 2016, 311, L743–L753. [Google Scholar] [CrossRef] [Green Version]
  29. Stamler, J.S.; Singel, D.J.; Loscalzo, J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992, 258, 1898–1902. [Google Scholar]
  30. Jia, J.; Arif, A.; Terenzi, F.; Willard, B.; Plow, E.F.; Hazen, S.L.; Fox, P.L. Target-selective protein S-nitrosylation by sequence motif recognition. Cell 2014, 159, 623–634. [Google Scholar] [CrossRef] [Green Version]
  31. Kornberg, M.D.; Sen, N.; Hara, M.R.; Juluri, K.R.; Nguyen, J.V.; Snowman, A.M.; Law, L.; Hester, L.D.; Snyder, S.H. GAPDH mediates nitrosylation of nuclear proteins. Nat. Cell Biol. 2010, 12, 1094–1100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Mitchell, D.A.; Marletta, M.A. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat. Chem. Biol. 2005, 1, 154–158. [Google Scholar] [CrossRef] [PubMed]
  33. Foster, M.W.; Hess, D.T.; Stamler, J.S. Protein S-nitrosylation in health and disease: A current perspective. Trends Mol. Med. 2009, 15, 391–404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Paige, J.S.; Xu, G.; Stancevic, B.; Jaffrey, S.R. Nitrosothiol reactivity profiling identifies S-nitrosylated proteins with unexpected stability. Chem. Biol. 2008, 15, 1307–1316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Gaston, B.; Reilly, J.; Drazen, J.M.; Fackler, J.; Ramdev, P.; Arnelle, D.; Mullins, M.E.; Sugarbaker, D.J.; Chee, C.; Singel, D.J.; et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc. Natl. Acad. Sci. USA 1993, 90, 10957–10961. [Google Scholar]
  36. Que, L.G.; Liu, L.; Yan, Y.; Whitehead, G.S.; Gavett, S.H.; Schwartz, D.A.; Stamler, J.S. Protection from experimental asthma by an endogenous bronchodilator. Science 2005, 308, 1618–1621. [Google Scholar] [CrossRef] [Green Version]
  37. Moore, P.E.; Ryckman, K.K.; Williams, S.M.; Patel, N.; Summar, M.L.; Sheller, J.R. Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma. Pediatr. Pulmonol. 2009, 44, 649–654. [Google Scholar] [CrossRef]
  38. Seth, D.; Hess, D.T.; Hausladen, A.; Wang, L.; Wang, Y.J.; Stamler, J.S. A Multiplex Enzymatic Machinery for Cellular Protein S-nitrosylation. Mol. Cell 2018, 69, 451–464. [Google Scholar] [CrossRef] [Green Version]
  39. Stamler, J.S.; Toone, E.J.; Lipton, S.A.; Sucher, N.J. (S)NO signals: Translocation, regulation, and a consensus motif. Neuron 1997, 18, 691–696. [Google Scholar]
  40. Choi, Y.B.; Tenneti, L.; Le, D.A.; Ortiz, J.; Bai, G.; Chen, H.S.; Lipton, S.A. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci. 2000, 3, 15–21. [Google Scholar] [CrossRef]
  41. Lillo, M.A.; Himelman, E.; Shirokova, N.; Xie, L.H.; Fraidenraich, D.; Contreras, J.E. S-nitrosylation of Connexin43 hemichannels elicits cardiac stress induced arrhythmias in Duchenne Muscular Dystrophy mice. JCI Insight 2019, 4, 130091. [Google Scholar] [CrossRef] [PubMed]
  42. Mannick, J.B.; Schonhoff, C.; Papeta, N.; Ghafourifar, P.; Szibor, M.; Fang, K.; Gaston, B. S-Nitrosylation of mitochondrial caspases. J. Cell Biol. 2001, 154, 1111–1116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Bryan, N.S.; Calvert, J.W.; Elrod, J.W.; Gundewar, S.; Ji, S.Y.; Lefer, D.J. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 2007, 104, 19144–19149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Stsiapura, V.I.; Bederman, I.; Stepuro, I.I.; Morozkina, T.S.; Lewis, S.J.; Smith, L.; Gaston, B.; Marozkina, N. S-Nitrosoglutathione formation at gastric pH is augmented by ascorbic acid and by the antioxidant vitamin complex, Resiston. Pharm. Biol. 2018, 56, 86–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Myers, P.R.; Minor, R.L., Jr.; Guerra, R., Jr.; Bates, J.N.; Harrison, D.G. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990, 345, 161–163. [Google Scholar] [CrossRef] [PubMed]
  46. Rosenblum, W.I. Endothelium-derived relaxing factor in brain blood vessels is not nitric oxide. Stroke 1992, 23, 1527–1532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Batenburg, W.W.; de Vries, R.; Saxena, P.R.; Danser, A.H. L-S-nitrosothiols: Endothelium-derived hyperpolarizing factors in porcine coronary arteries? J. Hypertens. 2004, 22, 1927–1936. [Google Scholar] [CrossRef]
  48. Batenburg, W.W.; Popp, R.; Fleming, I.; de Vries, R.; Garrelds, I.M.; Saxena, P.R.; Danser, A.H. Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF? Br. J. Pharmacol. 2004, 142, 125–135. [Google Scholar] [CrossRef] [Green Version]
  49. Davisson, R.L.; Travis, M.D.; Bates, J.N.; Lewis, S.J. Hemodynamic effects of L- and D-S-nitrosocysteine in the rat. Stereoselective S-nitrosothiol recognition sites. Circ. Res. 1996, 79, 256–262. [Google Scholar]
  50. Lewis, S.J.; Travis, M.D.; Bates, J.N. Stereoselective S-nitrosocysteine recognition sites in rat brain. Eur. J. Pharmacol. 1996, 312, R3–R5. [Google Scholar] [CrossRef]
  51. Davisson, R.L.; Travis, M.D.; Bates, J.N.; Johnson, A.K.; Lewis, S.J. Stereoselective actions of S-nitrosocysteine in central nervous system of conscious rats. Am. J. Physiol. 1997, 272, H2361–H2368. [Google Scholar] [CrossRef] [PubMed]
  52. Lewis, S.J.; Hoque, A.; Bates, J.N. Differentiation of L- and D-S-nitrosothiol recognition sites in vivo. J. Cardiovasc. Pharmacol. 2005, 46, 660–671. [Google Scholar] [CrossRef] [PubMed]
  53. Lang, R.J.; Harvey, J.R.; Mulholland, E.L. Sodium (2-sulfonatoethyl) methanethiosulfonate prevents S-nitroso-l-cysteine activation of Ca2+-activated K+ (BKCa) channels in myocytes of the guinea-pig taenia caeca. Br. J. Pharmacol. 2003, 139, 1153–1163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Travis, M.D.; Hoque, A.; Bates, J.N.; Lewis, S.J. Blockade of voltage-sensitive Ca(2+)-channels markedly diminishes nitric oxide- but not L-S-nitrosocysteine- or endothelium-dependent vasodilation in vivo. Eur. J. Pharmacol. 2000, 408, 289–298. [Google Scholar] [CrossRef]
  55. Seth, P.; Hsieh, P.N.; Jamal, S.; Wang, L.; Gygi, S.P.; Jain, M.K.; Coller, J.; Stamler, J.S. Regulation of MicroRNA Machinery and Development by Interspecies S-Nitrosylation. Cell 2019, 176, 1014–1025. [Google Scholar] [CrossRef] [Green Version]
  56. Fang, K.; Johns, R.; Macdonald, T.; Kinter, M.; Gaston, B. S-nitrosoglutathione breakdown prevents airway smooth muscle relaxation in the guinea pig. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, L716–L721. [Google Scholar]
  57. Benhar, M.; Forrester, M.T.; Hess, D.T.; Stamler, J.S. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 2008, 320, 1050–1054. [Google Scholar] [CrossRef] [Green Version]
  58. Haendeler, J.; Hoffmann, J.; Tischler, V.; Berk, B.C.; Zeiher, A.M.; Dimmeler, S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat. Cell Biol. 2002, 4, 743–749. [Google Scholar] [CrossRef]
  59. Bateman, R.L.; Rauh, D.; Tavshanjian, B.; Shokat, K.M. Human carbonyl reductase 1 is an S-nitrosoglutathione reductase. J. Biol. Chem. 2008, 283, 35756–35762. [Google Scholar]
  60. Trujillo, M.; Alvarez, M.N.; Peluffo, G.; Freeman, B.A.; Radi, R. Xanthine oxidase-mediated decomposition of S-nitrosothiols. J. Biol. Chem. 1998, 273, 7828–7834. [Google Scholar]
  61. Johnson, M.A.; Macdonald, T.L.; Mannick, J.B.; Conaway, M.R.; Gaston, B. Accelerated s-nitrosothiol breakdown by amyotrophic lateral sclerosis mutant copper, zinc-superoxide dismutase. J. Biol. Chem. 2001, 276, 39872–39878. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Ramachandran, N.; Root, P.; Jiang, X.M.; Hogg, P.J.; Mutus, B. Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulfide isomerase. Proc. Natl. Acad. Sci. USA 2001, 98, 9539–9544. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Stomberski, C.T.; Anand, P.; Venetos, N.M.; Hausladen, A.; Zhou, H.L.; Premont, R.T.; Stamler, J.S. AKR1A1 is a novel mammalian S-nitroso-glutathione reductase. J. Biol. Chem. 2019, 294, 18285–18293. [Google Scholar] [CrossRef] [PubMed]
  64. Wu, H.; Romieu, I.; Sienra-Monge, J.J.; Estela Del Rio-Navarro, B.; Anderson, D.M.; Jenchura, C.A.; Li, H.; Ramirez-Aguilar, M.; Del Carmen Lara-Sanchez, I.; London, S.J. Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma. J. Allergy Clin. Immunol. 2007, 120, 322–328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Choudhry, S.; Que, L.G.; Yang, Z.; Liu, L.; Eng, C.; Kim, S.O.; Kumar, G.; Thyne, S.; Chapela, R.; Rodriguez-Santana, J.R.; et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: Bronchodilator responsiveness to albuterol. Pharmacogenet. Genomics 2010, 20, 351–358. [Google Scholar] [CrossRef] [Green Version]
  66. Marozkina, N.V.; Wang, X.Q.; Stsiapura, V.; Fitzpatrick, A.; Carraro, S.; Hawkins, G.A.; Bleecker, E.; Meyers, D.; Jarjour, N.; Fain, S.B.; et al. Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity. Eur. Respir. J. 2015, 45, 87–97. [Google Scholar] [CrossRef] [Green Version]
  67. Shen, X.; Kolluru, G.K.; Yuan, S.; Kevil, C.G. Measurement of H2S in vivo and in vitro by the monobromobimane method. Methods Enzymol. 2015, 554, 31–45. [Google Scholar] [CrossRef] [Green Version]
  68. Wintner, E.A.; Deckwerth, T.L.; Langston, W.; Bengtsson, A.; Leviten, D.; Hill, P.; Insko, M.A.; Dumpit, R.; VandenEkart, E.; Toombs, C.F.; et al. A monobromobimane-based assay to measure the pharmacokinetic profile of reactive sulphide species in blood. Br. J. Pharmacol. 2010, 160, 941–957. [Google Scholar] [CrossRef] [Green Version]
  69. Sonobe, T.; Haouzi, P. H2S concentrations in the heart after acute H2S administration: Methodological and physiological considerations. Am. J. Physiol. Heart Circ. Physiol. 2016, 311, H1445–H1458. [Google Scholar] [CrossRef]
  70. Prabhakar, N.R. Carbon monoxide (CO) and hydrogen sulfide (H(2)S) in hypoxic sensing by the carotid body. Respir. Physiol. Neurobiol. 2012, 184, 165–169. [Google Scholar] [CrossRef] [Green Version]
  71. Shibuya, N.; Mikami, Y.; Kimura, Y.; Nagahara, N.; Kimura, H. Vascular Endothelium Expresses 3-Mercaptopyruvate Sulfurtransferase and Produces Hydrogen Sulfide. J. Biochem. 2009, 146, 623–626. [Google Scholar] [CrossRef] [PubMed]
  72. Vellecco, V.; Mancini, A.; Ianaro, A.; Calderone, V.; Attanasio, C.; Cantalupo, A.; Andria, B.; Savoia, G.; Panza, E.; Di Martino, A.; et al. Cystathionine beta-synthase-derived hydrogen sulfide is involved in human malignant hyperthermia. Clin. Sci. 2016, 130, 35–44. [Google Scholar] [CrossRef] [PubMed]
  73. Alvarez, C.; Calo, L.; Romero, L.C.; Garcia, I.; Gotor, C. An O-acetylserine(thiol)lyase homolog with L-cysteine desulfhydrase activity regulates cye homeostasis in Arabidopsis. Plant Physiol. 2010, 152, 656–669. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Reis, A.; Stern, A.; Monteiro, H.P. S-nitrosothiols and H2S donors: Potential chemo-therapeutic agents in cancer. Redox Biol. 2019, 27, 101190. [Google Scholar] [CrossRef]
  75. Wilson, K.; Mudra, M.; Furne, J.; Levitt, M. Differentiation of the roles of sulfide oxidase and rhodanese in the detoxification of sulfide by the colonic mucosa. Dig. Dis. Sci. 2008, 53, 277–283. [Google Scholar] [CrossRef]
  76. Jackson, M.R.; Melideo, S.L.; Jorns, M.S. Human sulfide:quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite. Biochemistry 2012, 51, 6804–6815. [Google Scholar] [CrossRef]
  77. Zhao, W.; Zhang, J.; Lu, Y.; Wang, R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001, 20, 6008–6016. [Google Scholar] [CrossRef] [Green Version]
  78. Mustafa, A.K.; Gadalla, M.M.; Sen, N.; Kim, S.; Mu, W.; Gazi, S.K.; Barrow, R.K.; Yang, G.; Wang, R.; Snyder, S.H. H2S signals through protein S-sulfhydration. Sci. Signal. 2009, 2, ra72. [Google Scholar] [CrossRef] [Green Version]
  79. Lu, C.; Kavalier, A.; Lukyanov, E.; Gross, S.S. S-sulfhydration/desulfhydration and S-nitrosylation/denitrosylation: A common paradigm for gasotransmitter signaling by HS and NO. Methods 2013, 62, 177–181. [Google Scholar] [CrossRef]
  80. Hara, M.R.; Agrawal, N.; Kim, S.F.; Cascio, M.B.; Fujimuro, M.; Ozeki, Y.; Takahashi, M.; Cheah, J.H.; Tankou, S.K.; Hester, L.D.; et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat. Cell Biol. 2005, 7, 665–674. [Google Scholar] [CrossRef]
  81. Eberhardt, M.; Dux, M.; Namer, B.; Miljkovic, J.; Cordasic, N.; Will, C.; Kichko, T.I.; de la Roche, J.; Fischer, M.; Suarez, S.A.; et al. H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. Nat. Commun. 2014, 5, 4381. [Google Scholar] [CrossRef] [PubMed]
  82. Hosoki, R.; Matsuki, N.; Kimura, H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem. Biophys. Res. Commun. 1997, 237, 527–531. [Google Scholar] [CrossRef] [PubMed]
  83. Coletta, C.; Papapetropoulos, A.; Erdelyi, K.; Olah, G.; Modis, K.; Panopoulos, P.; Asimakopoulou, A.; Gero, D.; Sharina, I.; Martin, E.; et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc. Natl. Acad. Sci. USA 2012, 109, 9161–9166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Szijarto, I.A.; Marko, L.; Filipovic, M.R.; Miljkovic, J.L.; Tabeling, C.; Tsvetkov, D.; Wang, N.; Rabelo, L.A.; Witzenrath, M.; Diedrich, A.; et al. Cystathionine gamma-Lyase-Produced Hydrogen Sulfide Controls Endothelial NO Bioavailability and Blood Pressure. Hypertension 2018, 71, 1210–1217. [Google Scholar] [CrossRef]
  85. Yang, G.; Wu, L.; Jiang, B.; Yang, W.; Qi, J.; Cao, K.; Meng, Q.; Mustafa, A.K.; Mu, W.; Zhang, S.; et al. H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008, 322, 587–590. [Google Scholar] [CrossRef] [Green Version]
  86. Cirino, G.; Vellecco, V.; Bucci, M. Nitric oxide and hydrogen sulfide: The gasotransmitter paradigm of the vascular system. Br. J. Pharmacol. 2017, 174, 4021–4031. [Google Scholar] [CrossRef] [Green Version]
  87. Bucci, M.; Papapetropoulos, A.; Vellecco, V.; Zhou, Z.; Pyriochou, A.; Roussos, C.; Roviezzo, F.; Brancaleone, V.; Cirino, G. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1998–2004. [Google Scholar] [CrossRef] [Green Version]
  88. Bucci, M.; Papapetropoulos, A.; Vellecco, V.; Zhou, Z.; Zaid, A.; Giannogonas, P.; Cantalupo, A.; Dhayade, S.; Karalis, K.P.; Wang, R.; et al. cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. PLoS ONE 2012, 7, e53319. [Google Scholar] [CrossRef] [Green Version]
  89. Wallace, J.L.; Wang, R. Hydrogen sulfide-based therapeutics: Exploiting a unique but ubiquitous gasotransmitter. Nat. Rev. Drug Discov. 2015, 14, 329–345. [Google Scholar] [CrossRef]
  90. Wang, R. Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol. Rev. 2012, 92, 791–896. [Google Scholar] [CrossRef] [Green Version]
  91. Pietri, R.; Roman-Morales, E.; Lopez-Garriga, J. Hydrogen sulfide and hemeproteins: Knowledge and mysteries. Antioxid. Redox Signal. 2011, 15, 393–404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Mishanina, T.V.; Libiad, M.; Banerjee, R. Biogenesis of reactive sulfur species for signaling by hydrogen sulfide oxidation pathways. Nat. Chem. Biol. 2015, 11, 457–464. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Olson, K.R.; Straub, K.D. The Role of Hydrogen Sulfide in Evolution and the Evolution of Hydrogen Sulfide in Metabolism and Signaling. Physiology 2016, 31, 60–72. [Google Scholar] [CrossRef] [PubMed]
  94. Vitvitsky, V.; Yadav, P.K.; Kurthen, A.; Banerjee, R. Sulfide Oxidation by a Noncanonical Pathway in Red Blood Cells Generates Thiosulfate and Polysulfides. J. Biol. Chem. 2015, 290, 8310–8320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Bostelaar, T.; Vitvitsky, V.; Kumutima, J.; Lewis, B.E.; Yadav, P.K.; Brunold, T.C.; Filipovic, M.; Lehnert, N.; Stemmler, T.L.; Banerjee, R. Hydrogen Sulfide Oxidation by Myoglobin. J. Am. Chem. Soc. 2016, 138, 8476–8488. [Google Scholar] [CrossRef] [Green Version]
  96. Sharma, V.S.; Traylor, T.G.; Gardiner, R.; Mizukami, H. Reaction of nitric oxide with heme proteins and model compounds of hemoglobin. Biochemistry 1987, 26, 3837–3843. [Google Scholar] [CrossRef]
  97. Jensen, B.; Fago, A. Reactions of ferric hemoglobin and myoglobin with hydrogen sulfide under physiological conditions. J. Inorg. Biochem. 2018, 182, 133–140. [Google Scholar] [CrossRef]
  98. Choi, Y.B.; Lipton, S.A. Redox modulation of the NMDA receptor. Cell. Mol. Life Sci. 2000, 57, 1535–1541. [Google Scholar] [CrossRef]
  99. Li, Q.; Lancaster, J.R., Jr. Chemical foundations of hydrogen sulfide biology. Nitric Oxide 2013, 35, 21–34. [Google Scholar] [CrossRef] [Green Version]
  100. Filipovic, M.R.; Miljkovic, J.L.; Nauser, T.; Royzen, M.; Klos, K.; Shubina, T.; Koppenol, W.H.; Lippard, S.J.; Ivanović-Burmazović, I. Chemical characterization of the smallest S-nitrosothiol, HSNO; cellular cross-talk of H2S and S-nitrosothiols. J. Am. Chem. Soc. 2012, 134, 12016–12027. [Google Scholar] [CrossRef]
  101. Bruce King, S. Potential biological chemistry of hydrogen sulfide (H2S) with the nitrogen oxides. Free Radic. Biol. Med. 2013, 55, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Berenyiova, A.; Grman, M.; Mijuskovic, A.; Stasko, A.; Misak, A.; Nagy, P.; Ondriasova, E.; Cacanyiova, S.; Brezova, V.; Feelisch, M.; et al. The reaction products of sulfide and S-nitrosoglutathione are potent vasorelaxants. Nitric Oxide 2015, 46, 123–130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Islam, A.S.M.; Bhowmick, R.; Pal, K.; Katarkar, A.; Chaudhuri, K.; Ali, M. A Smart Molecule for Selective Sensing of Nitric Oxide: Conversion of NO to HSNO; Relevance of Biological HSNO Formation. Inorg. Chem. 2017, 56, 4324–4331. [Google Scholar] [CrossRef] [PubMed]
  104. Kang, J.; Xu, S.; Radford, M.N.; Zhang, W.; Kelly, S.S.; Day, J.J.; Xian, M. O-->S Relay Deprotection: A General Approach to Controllable Donors of Reactive Sulfur Species. Angew. Chem. Int. Ed. Engl. 2018, 57, 5893–5897. [Google Scholar] [CrossRef] [PubMed]
  105. Nava, M.; Martin-Drumel, M.A.; Lopez, C.A.; Crabtree, K.N.; Womack, C.C.; Nguyen, T.L.; Thorwirth, S.; Cummins, C.C.; Stanton, J.F.; McCarthy, M.C. Spontaneous and Selective Formation of HSNO, a Crucial Intermediate Linking H2S and Nitroso Chemistries. J. Am. Chem. Soc. 2016, 138, 11441–11444. [Google Scholar] [CrossRef] [PubMed]
  106. Ivanova, L.V.; Anton, B.J.; Timerghazin, Q.K. On the possible biological relevance of HSNO isomers: A computational investigation. Phys. Chem. Chem. Phys. 2014, 16, 8476–8486. [Google Scholar] [CrossRef] [PubMed]
Antioxidants 09 00225 g001 550
Figure 1. Eukaryotic thiol chemistry and the generation of thiol-based signaling molecules. Orange highlight shows product signaling molecules. AKR1A1—aldoketoreductase family 1 member 1A, CAT—cysteine aspartate aminotransferase, CBS—cystathionine b-synthase, CSE—cystathionine gamma lyase, CDO—cysteine deoxygenase, CoA—Coenzyme A, C-SNO—S-nitrosocysteine, GSNO—S-nitrosoglutathione, GSNOR—S-nitrosoglutathione reductase, GS—glutathione synthase, GCS—glutamylcysteine synthase, MAT—methionine adenosyltransferase; SAM- S-adenosyl methionine; 3MST—3 mercaptopuruvate sulfur transferase, PTA—pantetheinase, SNO-CoA—S-nitroso-Coenzyme A, γGT—γ-glutamyl transpeptidase.
Figure 1. Eukaryotic thiol chemistry and the generation of thiol-based signaling molecules. Orange highlight shows product signaling molecules. AKR1A1—aldoketoreductase family 1 member 1A, CAT—cysteine aspartate aminotransferase, CBS—cystathionine b-synthase, CSE—cystathionine gamma lyase, CDO—cysteine deoxygenase, CoA—Coenzyme A, C-SNO—S-nitrosocysteine, GSNO—S-nitrosoglutathione, GSNOR—S-nitrosoglutathione reductase, GS—glutathione synthase, GCS—glutamylcysteine synthase, MAT—methionine adenosyltransferase; SAM- S-adenosyl methionine; 3MST—3 mercaptopuruvate sulfur transferase, PTA—pantetheinase, SNO-CoA—S-nitroso-Coenzyme A, γGT—γ-glutamyl transpeptidase.
Antioxidants 09 00225 g001

Share and Cite

MDPI and ACS Style

Marozkina, N.; Gaston, B. An Update on Thiol Signaling: S-Nitrosothiols, Hydrogen Sulfide and a Putative Role for Thionitrous Acid. Antioxidants 2020, 9, 225. https://doi.org/10.3390/antiox9030225

AMA Style

Marozkina N, Gaston B. An Update on Thiol Signaling: S-Nitrosothiols, Hydrogen Sulfide and a Putative Role for Thionitrous Acid. Antioxidants. 2020; 9(3):225. https://doi.org/10.3390/antiox9030225

Chicago/Turabian Style

Marozkina, Nadzeya, and Benjamin Gaston. 2020. "An Update on Thiol Signaling: S-Nitrosothiols, Hydrogen Sulfide and a Putative Role for Thionitrous Acid" Antioxidants 9, no. 3: 225. https://doi.org/10.3390/antiox9030225

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop